Screener
Ultragenyx Pharmaceutical RARE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's total liabilities?
- Ultragenyx Pharmaceutical (RARE) reported total liabilities of $1.55B in Q2 2026.
- How has Ultragenyx Pharmaceutical's total liabilities changed year-over-year?
- Ultragenyx Pharmaceutical's total liabilities increased by 34.8% year-over-year, from $1.15B to $1.55B.
- What is the long-term trend for Ultragenyx Pharmaceutical's total liabilities?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total liabilities has grown at a 21.5% compound annual growth rate (CAGR), from $605.18M to $1.61B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Ultragenyx Pharmaceutical's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude